A Study on Evaluation of Anti-Emetics in the Prevention of Chemotherapy Induced Nausea and Vomiting in Cancer Patients in A Tertiary Care Hospital

Abstract

Background:The contemporary lifestyle has made Cancer as one of the most deadly diseases. Treatment modalities of cancer are many, while chemotherapy seems to be the most common. Though, chemotherapy subsides the disease, it has many side effects in which Chemotherapy induced Nausea and Vomiting (CINV) is frequent. This study aims to evaluate various antiemetics in the prevention of Chemotherapy induced Nausea and Vomiting in cancer patients specifically in Breast, Lung, Cervix and Head & Neck cancers so that the rate of emesis, efficacy and comparative efficacy of different antiemetic combinations in cancer patients can be determined. Methods: A prospective observational study was carried out at a tertiary care hospital in Tamilnadu, South India between January to June, 2015 in which 241 cancer patients receiving antiemetics in their prescriptions meeting our inclusion criteria were analyzed using standard guidelines. A well designed data collection form was prepared to collect the datas. Results: It was observed from our study that the efficacy of different combination of antiemetics, mostly given as triple based regimen, relied on the treatment regimen of the particular cancer, thereby its emetogenic level and NCI-CTC grading score and it was found out that Ramosetron based triple antiemetic regimen was slightly better than Granisetron based regimen to control CINV. Conclusion: It is the need of the h to promote optimal antiemetic medication and ensure that cancer patient receives evidence-based, effective treatments for their health problems.

Efficacy of Antiemetic Regimens for Prevention and Treatment of Chemotherapy-Induced Nausea and Vomiting in Patients of Breast Cancer Receiving Highly Emetogenic Chemotherapy

“…[10] Nausea and vomiting is a very distressing side effect induced by chemotherapy for solid tumors which not only occurs very commonly in almost 70%-80% individuals but is also recurrent, that is, the patient will experience it during every subsequent cycle as well. [11] This can lead to nonadherence to the chemotherapeutic treatment, which can affect disease progression and recurrence. Further, nausea and vomiting has severe effects on the quality of life with impaired functioning, increased anxiety, or depression.…”

“…The efficacy of different antiemetics can vary according to various factors such as patient characteristics, the type of chemotherapy received as well as the site of cancer tumors. [12] The addition of NK1 receptor antagonists to the antiemetic regimens has yielded a better armament for tackling CINV.…”